Skip to main content

Table 5 Relative risk of VTEs before and after STS diagnosis/index date: STS versus non-cancer cohort

From: Older soft tissue sarcoma patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data

STS subtypea

Before odds ratio (95% CI)

After hazard ratio (95% CI)

Angiosarcoma

4.0 (1.4, 11.1)+

9.1 (2.1, 39.5)+

Fibrosarcoma

0.5 (0.1, 2.0)

1.0 (0.1, 16.0)

GIST

1.0 (0.7, 1.4)

4.0 (2.8, 5.7)+

Leiomyosarcoma

1.5 (0.6, 3.5)

5.5 (2.1, 15.0)+

Liposarcoma

Not estimable

2.5 (0.9, 7.6)

MFHb

1.4 (0.6, 3.3)

19.7 (3.7, 106.0)+

NSTc

2.1 (0.8, 5.4)

4.4 (1.1, 17.5)+

Sarcoma NOSd

1.9 (1.4, 2.6)+

5.2 (3.8, 6.9)+

  1. All models adjusted for age at index/diagnosis date. Estimates represent the relative risk of VTE event in the 12 months before or after diagnosis/index date. STS patients 3,840; non-cancer patients = 3,480. VTE Venous Thromboembolic Event (including deep vein thrombosis,pulmonary embolism, and other thromboembolic events). OTE category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd-Chiari syndrome, and venous embolism/thrombosis of renal vein.
  2. aHazard ratios for STS subtypes other than those listed were not estimable due to small numbers.
  3. bMaligant fibrous histiocytoma.
  4. cNerve sheath tumor.
  5. dSarcoma not otherwise specified.
  6. +Statistically significant.
Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329